- Home
- GOSS vs NAN Comparison
GOSS vs NAN Comparison
Compare GOSS & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NAN
- Stock Information
- Founded
- GOSS 2015
- NAN 1999
- Country
- GOSS United States
- NAN United States
- Employees
- GOSS N/A
- NAN N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NAN Investment Managers
- Sector
- GOSS Health Care
- NAN Finance
- Exchange
- GOSS Nasdaq
- NAN Nasdaq
- Market Cap
- GOSS 347.8M
- NAN 342.0M
- IPO Year
- GOSS 2019
- NAN N/A
- Fundamental
- Price
- GOSS $2.47
- NAN $10.97
- Analyst Decision
- GOSS Strong Buy
- NAN
- Analyst Count
- GOSS 4
- NAN 0
- Target Price
- GOSS $8.50
- NAN N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- NAN 74.6K
- Earning Date
- GOSS 08-05-2025
- NAN 01-01-0001
- Dividend Yield
- GOSS N/A
- NAN 4.37%
- EPS Growth
- GOSS N/A
- NAN N/A
- EPS
- GOSS N/A
- NAN N/A
- Revenue
- GOSS $40,237,000.00
- NAN N/A
- Revenue This Year
- GOSS N/A
- NAN N/A
- Revenue Next Year
- GOSS $30.65
- NAN N/A
- P/E Ratio
- GOSS N/A
- NAN N/A
- Revenue Growth
- GOSS N/A
- NAN N/A
- 52 Week Low
- GOSS $0.66
- NAN $9.11
- 52 Week High
- GOSS $2.65
- NAN $11.34
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- NAN 37.01
- Support Level
- GOSS $2.38
- NAN $10.89
- Resistance Level
- GOSS $2.65
- NAN $10.94
- Average True Range (ATR)
- GOSS 0.15
- NAN 0.06
- MACD
- GOSS 0.03
- NAN -0.00
- Stochastic Oscillator
- GOSS 76.67
- NAN 33.33
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.